A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease

Area of Science:

• Gastroenterology
• Biomarker Discovery
• Clinical Nutrition

Background:

• Crohn's disease (CD) monitoring often relies on patient-disliked fecal and blood sampling.
• Urine analysis offers a potentially more acceptable alternative for assessing CD activity.

Purpose of the Study:

• To evaluate urine biomarkers for Crohn's disease (CD) activity.
• To assess changes in urinary biomarkers before and after exclusive enteral nutrition (EEN) therapy.

Main Methods:

• Urine samples from 14 adults with active CD were analyzed for intestinal fatty acid-binding protein (I-FABP), liver fatty acid-binding protein (L-FABP), claudin-3, and calprotectin.
• Biomarker levels were correlated with clinical parameters and assessed pre- and post-EEN therapy.

Main Results:

• Urinary I-FABP:Cr levels significantly decreased after EEN therapy.
• Urinary L-FABP:Cr levels increased post-EEN and correlated with serum IGF-1.
• Urinary claudin-3:Cr and calprotectin:Cr showed no significant changes.

Conclusions:

• Urinary I-FABP shows potential as a biomarker for CD disease activity in adults.
• Urinary L-FABP may serve as an indirect indicator of nutritional status in CD patients.
• Claudin-3 and calprotectin are unlikely to be useful urinary biomarkers for CD.